Sign inJoin waitlistJoin the waitlist

Matthew Galsky

Medical Oncology · Icahn School of Medicine at Mount Sinai

Credentials: · · · ·

History

Research

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm,…
The Lancet · 2016 · 2,972 citations
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
The Lancet · 2017 · 1,812 citations
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
The Lancet · 2020 · 1,345 citations

WO
William Oh
94 papers
GS
Guru Sonpavde
93 papers
John Sfakianos
55 papers
JR
Jonathan Rosenberg
54 papers
Joaquim Bellmunt
50 papers
CT
Che-Kai Tsao
48 papers · 1 as a fellow
Evan Yu
38 papers
NH
Noah Hahn
38 papers · 1 as a fellow
Sumanta Pal
33 papers
Neeraj Agarwal
32 papers
Matthew Milowsky
31 papers
Petros Grivas
31 papers

Grants

The Tisch Cancer Institute - Cancer Center Support Grant
National Cancer Institute · P30
Project lead · $1.4M · Icahn School of Medicine at Mount Sinai
2015–2030
Dissecting Myeloid Cell-Mediated Resistance to Immune Checkpoint Blockade in Bladder Cancer
National Cancer Institute · R01
PI · $3.5M · Icahn School of Medicine at Mount Sinai
2020–2025
Novel Approach to Facilitate Decisions in Patients w/ Muscle Invasive Bladder CA
National Cancer Institute · R21
PI · $449.8K · Feinstein Institute for Medical Research
2015–2018

Clinical trials

Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy
Principal investigator · Recruiting · Phase 1
National Cancer Institute (NCI)
2025–2027
Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer
Principal investigator · Recruiting · Phase 2
Matthew Galsky
2025–2029
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
Principal investigator · Recruiting · Phase 2, Phase 3
National Cancer Institute (NCI)
2024–2030
FL- 101 Study in Non-Metastatic MIBC
Principal investigator · Withdrawn · Early phase 1
Flame Biosciences
2022